Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Levin Calls Takeda/Shire Merger ‘Inspired,’ Says Entire Value Chain Must Address Pricing Issue

Executive Summary

Having previously criticized the biopharma industry for squandering the benefits of US tax reform, the former Teva CEO called for more M&A deals that offer a clear strategic rationale, pointing to Takeda/Shire as an example.

Advertisement

Related Content

Takeda Secures TiGenix But Investor Shire Concerns Bubble Up
BIO Notebook Day 2: Levin Scolds Industry For Squandering Proceeds From US Tax Reform
Takeda Grabs Shire At Last After Long Pursuit
Actavis’ Brent Saunders And Paul Bisaro Talk Innovation Vs. Discovery
Rx Industry Pricing Model Must Change, Former Merck CEO Vagelos Says

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC123237

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel